Skip to main content

Neuroscience at AbbVie: Parkinson’s Disease

The ongoing search for a way to cure Parkinson’s sparked a decades-long career in neurodegenerative disease research for AbbVie’s global Senior Medical Director in Neuroscience Development Maurizio Facheris.

A passion for the brain

At first, he may not have been the eager student in the first row in medical school, but Maurizio Facheris, M.D., had known he was interested in science, genetics and biology since high school. The Italian-born doctor believed that medicine allowed him to combine those interests with helping others. Initially, he thought his calling was as a cardio surgeon, but learning about the heart didn’t evoke the passion he felt when he sat in a different lecture. That lecture was about the brain. 

“For neurology, it was such a fascinating topic. Everything we feel and what we process comes from the brain,” Facheris says. “It’s not really your gut. It’s the brain and a bunch of neurotransmitters that create a thought, a feeling, or a movement. I just fell in love.” 

For the first time, Facheris says, he was in the front row. Later, during his medical residency in Milan, Italy, he took interest in neurodegenerative disease research, Parkinson’s specifically. Parkinson’s disease is a neurodegenerative disorder where neurons in the brain lose their ability to produce dopamine, which leads to muscular rigidity, tremors, and slowness of movement. 

In Canada, Parkinson’s disease (PD) affects more than 100,000 Canadians, with approximately 30 people diagnosed with the condition every day.  Within the next 10 years, this number is expected to increase to 163,700, and 50 new diagnoses per day.

The need for continued research and effective treatments served as motivation for Facheris, who watched both his uncle and his close friend, only 36 years old, struggle with the disease. 

“I thought if we could stop those neurons from dying and make them regrow, we could restore their function and, for example, help patients regain control of their movement,” Facheris says. “That’s compared to Alzheimer’s, where the main work is focused on preventing further degeneration. Once the neurons that created a memory are gone, that memory is gone forever, as well as the personality of that patient, even if we could put in new neurons.” 


A career move to reach thousands more

Always knowing Parkinson’s patients want a cure, Facheris took a role as medical director in neuroscience development at AbbVie. “I like that here at AbbVie, we’re looking at the patients from the very beginning to the very advanced stages of the disease.”

More than 20 years after falling in love with neurological research, Facheris is hopeful for the thousands of patients he’s connected with during his career. He says scientists have a better understanding of what’s happening within the proteins of the brain and how they could target them to help slow down the progression of the disease.

“When I came to AbbVie, I thought of my friend and of those 1,500 Parkinson’s patients I would see as a physician in Italy. I think of the patients I met while in the nonprofit sector, and I know here I can reach hundreds of thousands of people,” says Facheris. “Where we are today, I can say in my lifetime we will find an answer to modify Parkinson’s disease and slow progression and for that I’m excited and hopeful.”